Relapsed or Refractory Rhabdomyosarcoma

Centre Oscar Lambret Declares Addition of Temozolomide to Vincristine, Irinotecan May Improve Outcomes in Relapsed Rhabdomyosarcoma

Jun 2, 2019 | Cancer, Oncology, Relapsed or Refractory Rhabdomyosarcoma

French investigators reported the addition of temozolomide to vincristine and irinotecan may improve outcomes of children and adults with relapsed or refractory rhabdomyosarcoma, based on the results of a randomized Phase II study recently presented at ASCO reports...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Centre Oscar Lambret Declares Addition of Temozolomide to Vincristine, Irinotecan May Improve Outcomes in Relapsed Rhabdomyosarcoma

Pin It on Pinterest